Resveratrol for Knee Osteoarthritis: Pain, WOMAC, SIRT1 & 2026 Evidence

Resveratrol is not a proven treatment for knee osteoarthritis, but the 2025–2026 evidence has become genuinely interesting. The strongest direct trial—the 2024 multicenter phase 3 ARTHROL study—found no pain benefit over placebo. Newer randomized trials using 500 mg/day report improvements in WOMAC, walking pain, frailty, handgrip strength and balance.

Those newer findings should not be dismissed, but they also should not be presented as clean independent replication. The 2025 and 2026 papers come from the same investigator group, use the same 500 mg/day dose, similar recruitment settings and closely overlapping outcome batteries. Participant independence is uncertain from the public record.

The correct 2026 conclusion is therefore conflicting evidence, not proven efficacy.

Resveratrol and knee osteoarthritis at a glance

Study	Design	Dose	Main result
ARTHROL 2024	Multicenter double-blind phase 3 RCT, 142 participants	40 mg twice daily for 1 week, then 20 mg twice daily	No superiority over placebo for the primary knee-pain endpoint.
Karim 2025	Double-blind RCT, 123 participants	500 mg/day	Reported better frailty, walking pain, WOMAC, Oxford Knee Score and handgrip strength; plasma SIRT1 increased.
Karim 2026	Double-blind RCT, 129 participants	500 mg/day	Reported better balance, gait speed, knee ROM, handgrip, walking pain and WOMAC; some endpoints remained null.

What is the strongest knee-osteoarthritis trial?

The strongest direct efficacy study in the current corpus is the ARTHROL phase 3 randomized placebo-controlled trial, published in 2024.

Researchers recruited 142 adults with painful knee osteoarthritis across three French tertiary centers. Participants received a specific low-dose patented resveratrol formulation or matched placebo for six months.

At three months, knee pain improved by roughly 15 points in both groups. The between-group difference was only −0.6 points with a 95% confidence interval crossing zero, and the p value was 0.88.

In plain English: resveratrol did not outperform placebo for the primary pain endpoint.

ARTHROL was null—but not perfect

The investigators acknowledged that the trial was underpowered because the original assumed effect size was too optimistic. It also used a particular low-dose formulation, so the result should not be mechanically generalized to every dose or delivery system.

Still, ARTHROL carries substantial weight because it was multicenter, randomized, double-blind, placebo-controlled and phase 3, with a patient-centered pain endpoint.

A smaller positive trial should therefore not simply erase it.

The 2025 Karim trial: a much more positive result

In 2025, a randomized double-blind placebo-controlled trial enrolled 123 older adults with knee osteoarthritis and used 500 mg/day of resveratrol for 16 weeks.

The resveratrol group reportedly improved in:

• Fried frailty phenotype
• walking pain
• WOMAC score
• Oxford Knee Score
• handgrip strength

Knee flexion range of motion and gait speed did not significantly improve.

The trial also reported higher plasma SIRT1, which correlated with frailty scores.

What does the SIRT1 result mean?

The SIRT1 finding is mechanistically interesting, especially because resveratrol has long been marketed as a sirtuin-related longevity compound.

But two cautions matter:

1. A plasma SIRT1 change does not prove SIRT1 activation inside cartilage, synovium, skeletal muscle or other target tissues.
2. A correlation between SIRT1 and frailty does not prove that SIRT1 caused the symptom improvement.

The broader human SIRT1 literature is also inconsistent. A 2025 meta-analysis of randomized trials found no significant overall increase in SIRT1 gene expression, protein expression or circulating SIRT1.

See Resveratrol and SIRT1.

The 2026 Karim paper: balance and function improve

A 2026 randomized double-blind trial from the same research group enrolled 129 adults with knee osteoarthritis and postural imbalance and again used 500 mg/day.

Reported improvements included:

• postural balance
• gait speed
• knee range of motion
• handgrip strength
• walking pain
• WOMAC score

Oxford Knee Score and resting pain did not significantly improve. Plasma SIRT1 increased and C-reactive protein decreased.

Are the 2025 and 2026 trials independent replications?

We should not assume so.

The two papers share:

• the same four investigators
• the same 500 mg/day intervention
• closely related knee-OA populations
• similar recruitment setting
• multiple overlapping endpoints
• similar age range and study duration

Without clear participant-level confirmation, the safest evidence practice is to treat them as related publications or potentially overlapping cohorts, not as two clean independent replications.

This matters because counting publications instead of independent participants can make an evidence base look stronger than it is.

Why dose might matter—but is not the whole explanation

The contrast is striking: ARTHROL used a much lower daily resveratrol amount than the newer 500 mg/day trials.

It is therefore reasonable to ask whether dose contributed to the different results. But dose is only one difference. The trials also differed in:

• formulation
• population
• centers and investigators
• outcome selection
• study duration
• statistical plan

We cannot conclude from these three studies that “500 mg works and low doses do not.” That would require direct dose-comparison evidence.

Could bioavailability explain the conflicting results?

Possibly, but it is unproven. Resveratrol formulations can produce very different systemic exposure. A 2025 randomized crossover pharmacokinetic study showed almost a five-fold difference in peak total-resveratrol concentration between two oral formulations.

However, no knee-OA trial has established a clear exposure-response relationship connecting higher plasma exposure with better pain or function.

See Resveratrol Bioavailability.

What is WOMAC and why does it matter?

WOMAC—the Western Ontario and McMaster Universities Osteoarthritis Index—is a commonly used patient-reported measure covering pain, stiffness and physical function in osteoarthritis.

Improvement in WOMAC can be clinically meaningful, but interpretation depends on the size of the change, between-group difference, baseline severity and whether the result is supported by other patient-centered outcomes.

That is why a positive WOMAC result should be interpreted alongside the null ARTHROL primary pain result rather than in isolation.

Does resveratrol reduce osteoarthritis inflammation?

There is a plausible anti-inflammatory mechanism, and the 2026 trial reported lower C-reactive protein. Resveratrol also affects inflammatory signaling in broader human and experimental research.

But lower CRP does not prove reduced synovitis, cartilage preservation or slower structural disease progression.

Does resveratrol rebuild cartilage?

No human evidence supports a claim that oral resveratrol rebuilds cartilage. Most clinical trials measure symptoms, function and blood biomarkers, not cartilage regeneration.

Cell and animal studies on cartilage biology should not be converted into a human “joint rebuilding” claim.

Does resveratrol slow osteoarthritis progression?

Not established. To prove disease modification, trials would need convincing structural outcomes over adequate follow-up—not simply less pain or a biomarker shift.

Current human studies do not establish that resveratrol slows joint-space loss or preserves cartilage over the long term.

What dose has been studied for knee osteoarthritis?

The human knee-OA trials in the current corpus used very different regimens:

• ARTHROL: initially 80 mg/day, then 40 mg/day
• Karim 2025: 500 mg/day
• Karim 2026: 500 mg/day

No optimal osteoarthritis dose has been established.

See Resveratrol Dosage.

Can resveratrol replace NSAIDs or other osteoarthritis treatment?

No. The evidence is too inconsistent to substitute resveratrol for established osteoarthritis management.

Management can include exercise, weight management when relevant, physical therapy, topical or oral medications, injections in selected cases and surgery for advanced disease. The right strategy depends on symptoms, comorbidities and severity.

Who should be cautious?

People with osteoarthritis are often older and may take anticoagulants, antiplatelet drugs, antihypertensives, diabetes medication or other prescriptions. Resveratrol can affect CYP drug-metabolizing enzymes and platelet-related biology.

Read Resveratrol Drug Interactions and Resveratrol Side Effects.

Bottom line

Knee osteoarthritis is one of the most interesting—and most contradictory—areas in the current resveratrol evidence base.

The correct summary is not that resveratrol “failed” because ARTHROL was null, nor that it “works” because the newer 500 mg trials are positive. The phase 3 trial deserves substantial weight, while the newer studies deserve replication by independent teams with clearly non-overlapping cohorts and comparable endpoints.

For the mechanism, see Resveratrol and SIRT1. For dose and formulation context, see Resveratrol Dosage and Bioavailability. All three knee-OA records are linked in the Resveratrol Data Center.